ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Tarsus Pharmaceuticals, Inc. ?
1
With a growth in Net Sales of 6.85%, the company declared Outstanding results in Mar 26
- The company has declared positive results for the last 7 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -16.45 MM
- ROCE(HY) Highest at -13.96%
- NET SALES(Q) Highest at USD 162.05 MM
2
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
3
Consistent Returns over the last 3 years
- Along with generating 62.98% returns in the last 1 year, the stock has outperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Tarsus Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Tarsus Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Tarsus Pharmaceuticals, Inc.
62.98%
2.27
45.89%
S&P 500
22.24%
1.67
13.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
239.70%
EBIT Growth (5y)
-191.19%
EBIT to Interest (avg)
-28.08
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.98
Sales to Capital Employed (avg)
0.48
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.21
EV to EBIT
-34.86
EV to EBITDA
-35.75
EV to Capital Employed
-1259.70
EV to Sales
5.48
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-19.34%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend40What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -16.45 MM
ROCE(HY)
Highest at -13.96%
NET SALES(Q)
Highest at USD 162.05 MM
OPERATING PROFIT(Q)
Highest at USD -5.68 MM
OPERATING PROFIT MARGIN(Q)
Highest at -3.51 %
PRE-TAX PROFIT(Q)
Highest at USD -4.62 MM
NET PROFIT(Q)
Highest at USD -6.97 MM
RAW MATERIAL COST(Y)
Fallen by -0.92% (YoY
CASH AND EQV(HY)
Highest at USD 806.56 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 9.58 times
EPS(Q)
Highest at USD -0.16
-4What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at -85.99 %
Here's what is working for Tarsus Pharmaceuticals, Inc.
Operating Cash Flow
Highest at USD -16.45 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Highest at USD 162.05 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Sales
At USD 162.05 MM has Grown at 43.61%
over average net sales of the previous four periods of USD 112.84 MMMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Profit
Highest at USD -5.68 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at -3.51 % and Grown
In each period in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD -4.62 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -6.97 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Pre-Tax Profit
At USD -4.62 MM has Grown at 71.32%
over average net sales of the previous four periods of USD -16.09 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -6.97 MM has Grown at 58.04%
over average net sales of the previous four periods of USD -16.6 MMMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.16
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Cash and Eqv
Highest at USD 806.56 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Inventory Turnover Ratio
Highest at 9.58 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by -0.92% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Tarsus Pharmaceuticals, Inc.
Debt-Equity Ratio
Highest at -85.99 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
